rexin-g
Biologicalexperimental
Clinical trial activity
8 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2002 (NCT00035919)
Timeline
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mx-dng1 retroviral vector
- rexin-g
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04378244 | Phase 1/Phase 2 (Phase 2) | Jun 12, 2020 | Aveni Foundation, Mission Community Hospital |
| NCT00572130 | Phase 2 | Dec 1, 2007 | Epeius Biotechnologies |
| NCT00505271 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2007 | Bruckner Oncology, Epeius Biotechnologies |
| NCT00505713 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2007 | Epeius Biotechnologies |
| NCT00504998 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2007 | Bruckner Oncology, Epeius Biotechnologies |
| NCT00121745 | Phase 1 | Jul 1, 2005 | Epeius Biotechnologies, Mayo Clinic |
| NCT00035919 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2002 | University of Southern California |
| NCT04091295 | N/A | — | Aveni Foundation, Sarcoma Oncology Research Center, LLC |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Epeius Biotechnologies | For profit | 5 | 5 | 2 | 2005 |
| Aveni Foundation | Academic/Hospital | 2 | 2 | 2 | 2020 |
| Bruckner Oncology | Academic/Hospital | 2 | 0 | 1 | 2007 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Mission Community Hospital | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Sarcoma Oncology Research Center, LLC | Academic/Hospital | 1 | 0 | 1 | — |
| University of Southern California | Academic/Hospital | 1 | 1 | 1 | 2002 |
7 organizations
Page 1 / 1